Basilea Pharmaceutica AG (SWX:BSLN)

Market Cap	622.27M +14.5%
Revenue (ttm)	232.38M +11.4%
Net Income	40.24M -48.1%
EPS	3.14 -46.1%
Shares Out	12.40M
PE Ratio	15.98
Forward PE	11.79
Dividend	n/a
Ex-Dividend Date	n/a

Volume	51,157
Open	50.20
Previous Close	50.20
Day's Range	49.00 - 50.20
52-Week Range	44.70 - 59.70
Beta	0.41
Analysts	Buy
Price Target	89.90 (+81.25%)
Earnings Date	Aug 18, 2026

About Basilea Pharmaceutica AG

Basilea Pharmaceutica AG is a Swiss commercial-stage biotech company focused on developing and commercializing treatments for severe bacterial and fungal infections. The company offers Cresemba (isavuconazole), an intravenous and oral antifungal for the treatment of invasive aspergillosis and mucormycosis; and Zevtera (ceftobiprole), an antibiotic for the treatment of pneumonia, Staphylococcus aureus bacteremia (SAB), acute bacterial skin, community-acquired bacterial pneumonia, and skin structure infections (ABSSSI). The company also has a cli...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 189
• Stock Exchange: SIX Swiss Exchange
• Ticker Symbol: BSLN

Financial Performance

In 2025, Basilea Pharmaceutica AG's revenue was 232.38 million, an increase of 11.43% compared to the previous year's 208.54 million. Earnings were 40.24 million, a decrease of -48.14%.

Analyst Summary

According to 4 analysts, the average rating for BSLN stock is "Buy." The 12-month stock price target is CHF 89.90, which is an increase of 81.25% from the latest price.

Price Target

CHF 89.90

(81.25% upside)

Analyst Consensus: Buy